PROTOCOL SPECIFIC RESEARCH RESOURCE

赫伯特·欧文综合癌症中心参与了广泛的创新、可行性或 原则性证明试验源于其研究方案，由机构私人投资机构发起。登记参加 这些研究在上一次赠款期间一直保持不变。这些研究的进行是 由临床研究管理部提供的研究护理和数据管理支持 办公室(CRMO)。研究护理只关注患者的资格、同意和管理 正在进行临床试验。除了参与高优先级临床试验的范围外，赫伯特·欧文 综合癌症中心进行了一系列癌症疫苗和癌症疫苗的创新I期试验 免疫疗法已经提供了关于这些疾病的机制和临床疗效的重要信息 探员们。人们越来越重视基础科学和临床研究之间的互动，因为 正在进行的乳腺癌和淋巴瘤的翻译研究就是例证。扩展对我们的 要求参加高度优先和创新的试验。 《议定书》特定研究支助的预计业务预算为352,247美元，其中我们 请求CCSG提供100%支持。

The Herbert Irving Comprehensive Cancer Center participates in a wide range of innovative, feasibility or proof of principle trials originating from its research programs and initiated by institutional Pis. Enrollment in these studies has been maintained throughout the last grant period. The conduct of these studies is supported by research nursing and data management provided by the Clinical Research Management Office (CRMO). Research Nursing focuses solely on the eligibility, consenting and management of patients on clinical trials. In addition to its participation in the scope of high-priority clinical trials, Herbert Irving Comprehensive Cancer Center has conducted a series of innovative phase I trials of cancer vaccines and immunotherapy that have provided important information on the mechanisms and clinical efficacy of these agents. There is an increasing emphasis on interaction between basic science and clinical research as exemplified by ongoing translational studies in breast cancer and lymphoma. Expanded support for our participation in high priority and innovative trials is requested. The projected operating budget for Protocol Specific Research Support is $352,247, of which we are requesting 100% support from the CCSG.